RG 125

Drug Profile

RG 125

Alternative Names: AZD 4076; RG125

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator AstraZeneca; Regulus Therapeutics
  • Class Antisense oligonucleotides; MicroRNAs
  • Mechanism of Action MIRN103 microRNA modulators; MIRN107 microRNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-alcoholic fatty liver disease
  • Phase I Non-alcoholic steatohepatitis

Most Recent Events

  • 01 Dec 2016 AstraZeneca completes the phase I trial for Non-alcoholic steatohepatitis in USA (NCT02612662)
  • 05 Jul 2016 AstraZeneca plans a phase I/IIa trial for Non-alcoholic fatty liver disease (in Type-2 Diabetes mellitus patients) in USA (SC) (NCT02826525)
  • 01 Jul 2016 Phase-I/II clinical trials in Non-alcoholic fatty liver disease in USA (SC) (NCT02826525)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top